USRE39608E1 - Substituted benzimidazoles and their use as PARP inhibitors - Google Patents
Substituted benzimidazoles and their use as PARP inhibitors Download PDFInfo
- Publication number
- USRE39608E1 USRE39608E1 US10/935,683 US93568399A USRE39608E US RE39608 E1 USRE39608 E1 US RE39608E1 US 93568399 A US93568399 A US 93568399A US RE39608 E USRE39608 E US RE39608E
- Authority
- US
- United States
- Prior art keywords
- alkyl
- benzimidazole
- carboxamide
- compound
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 *C1=NC2=C(C(C(N)=O)=CC=C2)N1[1*].*C1=NC2=C(C=CC=C2C(N)=O)N1[1*].[4*]C.[4*]C Chemical compound *C1=NC2=C(C(C(N)=O)=CC=C2)N1[1*].*C1=NC2=C(C=CC=C2C(N)=O)N1[1*].[4*]C.[4*]C 0.000 description 6
- FZPBTTBNHGXUNS-UHFFFAOYSA-N C.NC(=O)C1=C2N=C(C3CCNCC3)NC2=CC=C1 Chemical compound C.NC(=O)C1=C2N=C(C3CCNCC3)NC2=CC=C1 FZPBTTBNHGXUNS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19854933 | 1998-11-27 | ||
DE1999116460 DE19916460B4 (de) | 1999-04-12 | 1999-04-12 | Substituierte Benzimidazole, deren Herstellung und Anwendung |
PCT/EP1999/009004 WO2000032579A1 (de) | 1998-11-27 | 1999-11-23 | Substituierte benzimidazole und ihre verwendung als parp inhibitoren |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/856,686 Reissue US6448271B1 (en) | 1998-11-27 | 1999-11-23 | Substituted benzimidazoles and their use as parp inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE39608E1 true USRE39608E1 (en) | 2007-05-01 |
Family
ID=26050434
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/935,683 Expired - Lifetime USRE39608E1 (en) | 1998-11-27 | 1999-11-23 | Substituted benzimidazoles and their use as PARP inhibitors |
US09/856,686 Ceased US6448271B1 (en) | 1998-11-27 | 1999-11-23 | Substituted benzimidazoles and their use as parp inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/856,686 Ceased US6448271B1 (en) | 1998-11-27 | 1999-11-23 | Substituted benzimidazoles and their use as parp inhibitors |
Country Status (32)
Country | Link |
---|---|
US (2) | USRE39608E1 (de) |
EP (1) | EP1133477B1 (de) |
JP (1) | JP3432800B2 (de) |
KR (1) | KR100417779B1 (de) |
CN (1) | CN1184208C (de) |
AR (1) | AR021400A1 (de) |
AT (1) | ATE259789T1 (de) |
AU (1) | AU764216B2 (de) |
BG (1) | BG65047B1 (de) |
BR (1) | BR9915701A (de) |
CA (1) | CA2352554C (de) |
CZ (1) | CZ300148B6 (de) |
DE (1) | DE59908600D1 (de) |
DK (1) | DK1133477T3 (de) |
ES (1) | ES2216625T3 (de) |
HK (1) | HK1042084B (de) |
HR (1) | HRP20010484B1 (de) |
HU (1) | HUP0200749A3 (de) |
IL (2) | IL143303A0 (de) |
MY (1) | MY128488A (de) |
NO (1) | NO20012570L (de) |
NZ (1) | NZ511825A (de) |
PL (1) | PL196367B1 (de) |
PT (1) | PT1133477E (de) |
RU (1) | RU2001117757A (de) |
SI (1) | SI1133477T1 (de) |
SK (1) | SK285529B6 (de) |
TR (1) | TR200101498T2 (de) |
TW (1) | TWI247741B (de) |
UA (1) | UA61158C2 (de) |
WO (1) | WO2000032579A1 (de) |
ZA (1) | ZA200104118B (de) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060229351A1 (en) * | 2005-04-11 | 2006-10-12 | Gui-Dong Zhu | 2-Substituted-1 H-benzimidazile-4-carboxamides are PARP inhibitors |
US20060229289A1 (en) * | 2005-04-11 | 2006-10-12 | Gui-Dong Zhu | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors |
US20070179136A1 (en) * | 2005-09-29 | 2007-08-02 | Penning Thomas D | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
US20070259937A1 (en) * | 2006-05-02 | 2007-11-08 | Giranda Vincent L | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
US20070270476A1 (en) * | 2005-11-15 | 2007-11-22 | Penning Thomas D | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
US20070292883A1 (en) * | 2006-06-12 | 2007-12-20 | Ossovskaya Valeria S | Method of treating diseases with PARP inhibitors |
US20080103208A1 (en) * | 2006-09-05 | 2008-05-01 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
US20080103104A1 (en) * | 2006-09-05 | 2008-05-01 | Bipar Sciences, Inc. | Treatment of cancer |
US20080319054A1 (en) * | 2005-07-18 | 2008-12-25 | Bipar Sciences, Inc. | Treatment of Cancer |
US20090030016A1 (en) * | 2007-07-16 | 2009-01-29 | Abbott Laboratories | Benzimidazole poly(adp ribose)polymerase inhibitors |
US20090076122A1 (en) * | 2005-06-10 | 2009-03-19 | Bipar Sciences, Inc. | PARP Modulators and Treatment of Cancer |
US20090123419A1 (en) * | 2007-11-12 | 2009-05-14 | Bipar Sciences | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
US20090131529A1 (en) * | 2007-11-12 | 2009-05-21 | Bipar Sciences | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
US20100183743A1 (en) * | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010100977A (ko) | 1998-11-03 | 2001-11-14 | 스타르크, 카르크 | 치환된 2-페닐벤즈이미다졸, 그의 제조 및 그의 용도 |
DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
WO2001021615A1 (en) * | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
MXPA03000753A (es) * | 2000-08-08 | 2003-10-15 | Sanofi Synthelabo | Derivados de benzimidazola, su preparacion y su aplicacion terapeutica. |
FR2812878B1 (fr) * | 2000-08-08 | 2002-10-11 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
FR2816941B1 (fr) * | 2000-11-23 | 2003-01-31 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
FR2816942B1 (fr) * | 2000-11-23 | 2003-05-09 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
WO2002068407A1 (fr) * | 2001-02-28 | 2002-09-06 | Yamanouchi Pharmaceutical Co., Ltd. | Compose benzimidazole |
ES2291455T3 (es) | 2001-03-12 | 2008-03-01 | Avanir Pharmaceuticals | Compuestos de bencimidazol para modular ige e inhibir la proliferacion celular. |
US20040242635A1 (en) * | 2001-03-30 | 2004-12-02 | Painter Rachel J. | Encapsulated dyes in cosmetic compositions |
WO2003007959A1 (en) * | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
DE50310378D1 (de) | 2002-07-26 | 2008-10-02 | Basf Plant Science Gmbh | Neue selektionsverfahren |
WO2004014873A1 (ja) * | 2002-08-09 | 2004-02-19 | Kyorin Pharmaceutical Co., Ltd. | 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩 |
TWI276631B (en) | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
CA2501539A1 (en) * | 2002-10-17 | 2004-04-29 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
HU0301154D0 (en) * | 2003-04-28 | 2003-07-28 | Hideg Kalman Dr | Pharmaceutical composition |
EP2166100B1 (de) | 2005-03-08 | 2012-07-18 | BASF Plant Science GmbH | Expressionsverstärkende Intronsequenzen |
CN101142194B (zh) * | 2005-03-14 | 2012-10-10 | 顶点制药有限责任公司 | 吲哚衍生物,组合物及用作β-分泌酶抑制剂的方法 |
AU2012200399B2 (en) * | 2005-04-11 | 2013-07-11 | Abbvie Ireland Unlimited Company | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors |
CN101258658B (zh) | 2005-07-12 | 2012-11-14 | 麻省理工学院 | 无线非辐射能量传递 |
US7825543B2 (en) | 2005-07-12 | 2010-11-02 | Massachusetts Institute Of Technology | Wireless energy transfer |
EP1779849A1 (de) * | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase Inhibitoren zur Behandlung von septischem Schock |
US20090029966A1 (en) * | 2006-01-17 | 2009-01-29 | Abbott Laboratories | Combination therapy with parp inhibitors |
US20080293795A1 (en) * | 2006-01-17 | 2008-11-27 | Abbott Laboratories | Combination therapy with parp inhibitors |
US20070265324A1 (en) * | 2006-01-17 | 2007-11-15 | Wolfgang Wernet | Combination Therapy with Parp Inhibitors |
US20080280867A1 (en) * | 2006-01-17 | 2008-11-13 | Abbott Laboratories | Combination therapy with parp inhibitors |
US20080146638A1 (en) * | 2006-01-17 | 2008-06-19 | Abbott Laboratories | Combination therapy with parp inhibitors |
WO2007113596A1 (en) * | 2006-04-03 | 2007-10-11 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
EP2109608B1 (de) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amidsubstituierte indazole als poly-(adp-ribose)-polymerase (parp)-hemmer |
EP2591783A1 (de) * | 2007-04-13 | 2013-05-15 | Millennium Pharmaceuticals, Inc. | Gerinnungshemmende Kombinationstherapie mit einer Verbindung als Faktor-Xa-Hemmer |
US8138168B1 (en) * | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
EP2217603B1 (de) * | 2007-10-12 | 2015-11-18 | AbbVie Bahamas Ltd. | Kristalline form 2 von 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazol-4-carbonsäureamid |
CN106008460B (zh) | 2008-01-08 | 2022-08-12 | 默沙东公司 | 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐 |
EP2250282A4 (de) * | 2008-02-04 | 2011-05-18 | Bipar Sciences Inc | Verfahren zur diagnose und behandlung von parp-vermittelten krankheiten |
CN101998959B (zh) * | 2008-02-06 | 2013-08-28 | 生物马林药物股份有限公司 | 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂 |
WO2011002520A2 (en) | 2009-07-02 | 2011-01-06 | Angion Biomedica Corp. | Small molecule inhibitors of parp activity |
CN102686726B (zh) | 2009-11-27 | 2015-12-16 | 巴斯夫植物科学有限公司 | 嵌合内切核酸酶及其用途 |
BR112012012444A2 (pt) | 2009-11-27 | 2015-09-22 | Basf Plant Science Co Gmbh | "endonuclease quimérica, polinucleotídeo isolado, cassete de expressão, vetor, organismo não humano, método para fornecer uma endonuclease quimérica, método para recombinação homóloga de polinucleotídeos, método para mutação alvejada de polinucleotídeosa e método para recombinação homóloga ou mutação alvejada" |
AU2010325549B2 (en) | 2009-11-27 | 2017-04-20 | Basf Plant Science Company Gmbh | Optimized endonucleases and uses thereof |
EP2542533B1 (de) * | 2010-03-04 | 2014-09-10 | Bayer Intellectual Property GmbH | Fluoralkyl-substituierte 2-amidobenzimidazole und deren verwendung zur steigerung der stresstoleranz in pflanzen |
US20140051737A1 (en) * | 2011-05-10 | 2014-02-20 | Universite Laval | Methods for the treatment and diagnostic of pulmonary arterial hypertension |
EP2736896B1 (de) * | 2011-07-26 | 2016-12-14 | Nerviano Medical Sciences S.r.l. | 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivate als parp-1 inhibitoren |
EP2561759A1 (de) | 2011-08-26 | 2013-02-27 | Bayer Cropscience AG | Fluoralkyl-substituierte 2-amidobenzimidazole und ihre Wirkung auf das Pflanzenwachstum |
CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
CN102617502A (zh) * | 2012-03-19 | 2012-08-01 | 江苏先声药物研究有限公司 | 一类苯并噁唑衍生物及其医药应用 |
WO2014037340A1 (de) | 2012-09-05 | 2014-03-13 | Bayer Cropscience Ag | Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress |
GB201223265D0 (en) | 2012-12-21 | 2013-02-06 | Selvita Sa | Novel benzimidazole derivatives as kinase inhibitors |
CN104230897B (zh) * | 2013-06-17 | 2016-07-06 | 上海汇伦生命科技有限公司 | 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途 |
CN104230898B (zh) * | 2013-06-17 | 2016-06-29 | 上海汇伦生命科技有限公司 | 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途 |
CN103483322A (zh) * | 2013-08-21 | 2014-01-01 | 中国药科大学 | 5-氟-1h-苯并咪唑-4-甲酰胺衍生物、其制法及医药用途 |
CN103396405A (zh) * | 2013-08-21 | 2013-11-20 | 中国药科大学 | 具有parp抑制作用的苯并咪唑-4-甲酰胺衍生物 |
US10874641B2 (en) | 2016-07-28 | 2020-12-29 | Mitobridge, Inc. | Methods of treating acute kidney injury |
WO2018054989A1 (en) * | 2016-09-20 | 2018-03-29 | Centre Leon Berard | Benzoimidazole derivatives as anticancer agents |
MA46779A (fr) | 2016-11-02 | 2019-09-11 | Health Research Inc | Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp |
CN109232540A (zh) * | 2018-06-15 | 2019-01-18 | 深圳市坤健创新药物研究院 | 一种取代苯并咪唑衍生物及应用 |
CN108997320A (zh) * | 2018-08-30 | 2018-12-14 | 深圳市坤健创新药物研究院 | 一种含氟取代苯并咪唑衍生物及应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1354554U (de) | ||||
US4093726A (en) | 1976-12-02 | 1978-06-06 | Abbott Laboratories | N-(2-benzimidazolyl)-piperazines |
WO1997004771A1 (en) | 1995-08-02 | 1997-02-13 | Newcastle University Ventures Limited | Benzimidazole compounds |
WO1998033802A1 (en) | 1997-02-01 | 1998-08-06 | Newcastle University Ventures Limited | Quinazolinone compounds |
US5830905A (en) | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5877187A (en) | 1996-06-04 | 1999-03-02 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. (Faes) | Benzimidazole derivatives with antihistaminic activity |
US5958950A (en) | 1995-10-05 | 1999-09-28 | Warner-Lambert Company | Benzimidazole compounds useful for the treatment of inflammatory disease, atherosclerosis, restenosis or inhibiting lipoxygenase |
US5972980A (en) | 1995-10-05 | 1999-10-26 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US6001866A (en) | 1995-10-05 | 1999-12-14 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US6303627B1 (en) | 1998-06-19 | 2001-10-16 | Eli Lilly And Company | Inhibitors of serotonin reuptake |
-
1999
- 1999-11-23 AU AU30343/00A patent/AU764216B2/en not_active Ceased
- 1999-11-23 IL IL14330399A patent/IL143303A0/xx active IP Right Grant
- 1999-11-23 PL PL347884A patent/PL196367B1/pl unknown
- 1999-11-23 CN CNB998151130A patent/CN1184208C/zh not_active Expired - Fee Related
- 1999-11-23 TR TR2001/01498T patent/TR200101498T2/xx unknown
- 1999-11-23 SI SI9930543T patent/SI1133477T1/xx unknown
- 1999-11-23 BR BR9915701-2A patent/BR9915701A/pt not_active IP Right Cessation
- 1999-11-23 RU RU2001117757/04A patent/RU2001117757A/ru unknown
- 1999-11-23 HU HU0200749A patent/HUP0200749A3/hu unknown
- 1999-11-23 KR KR10-2001-7006611A patent/KR100417779B1/ko not_active IP Right Cessation
- 1999-11-23 JP JP2000585221A patent/JP3432800B2/ja not_active Expired - Fee Related
- 1999-11-23 WO PCT/EP1999/009004 patent/WO2000032579A1/de active IP Right Grant
- 1999-11-23 DE DE59908600T patent/DE59908600D1/de not_active Expired - Lifetime
- 1999-11-23 SK SK714-2001A patent/SK285529B6/sk not_active IP Right Cessation
- 1999-11-23 DK DK99964497T patent/DK1133477T3/da active
- 1999-11-23 PT PT99964497T patent/PT1133477E/pt unknown
- 1999-11-23 US US10/935,683 patent/USRE39608E1/en not_active Expired - Lifetime
- 1999-11-23 UA UA2001064494A patent/UA61158C2/uk unknown
- 1999-11-23 CA CA002352554A patent/CA2352554C/en not_active Expired - Fee Related
- 1999-11-23 US US09/856,686 patent/US6448271B1/en not_active Ceased
- 1999-11-23 AT AT99964497T patent/ATE259789T1/de active
- 1999-11-23 CZ CZ20011855A patent/CZ300148B6/cs not_active IP Right Cessation
- 1999-11-23 NZ NZ511825A patent/NZ511825A/en not_active IP Right Cessation
- 1999-11-23 ES ES99964497T patent/ES2216625T3/es not_active Expired - Lifetime
- 1999-11-23 EP EP99964497A patent/EP1133477B1/de not_active Expired - Lifetime
- 1999-11-25 AR ARP990106011A patent/AR021400A1/es unknown
- 1999-11-26 TW TW088120715A patent/TWI247741B/zh not_active IP Right Cessation
- 1999-11-27 MY MYPI99005192A patent/MY128488A/en unknown
-
2001
- 2001-05-21 ZA ZA200104118A patent/ZA200104118B/xx unknown
- 2001-05-22 IL IL143303A patent/IL143303A/en not_active IP Right Cessation
- 2001-05-25 NO NO20012570A patent/NO20012570L/no not_active Application Discontinuation
- 2001-06-13 BG BG105596A patent/BG65047B1/bg unknown
- 2001-06-26 HR HR20010484A patent/HRP20010484B1/xx not_active IP Right Cessation
-
2002
- 2002-05-04 HK HK02103400.6A patent/HK1042084B/zh not_active IP Right Cessation
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1354554U (de) | ||||
US4093726A (en) | 1976-12-02 | 1978-06-06 | Abbott Laboratories | N-(2-benzimidazolyl)-piperazines |
WO1997004771A1 (en) | 1995-08-02 | 1997-02-13 | Newcastle University Ventures Limited | Benzimidazole compounds |
US5958950A (en) | 1995-10-05 | 1999-09-28 | Warner-Lambert Company | Benzimidazole compounds useful for the treatment of inflammatory disease, atherosclerosis, restenosis or inhibiting lipoxygenase |
US5972980A (en) | 1995-10-05 | 1999-10-26 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US6001866A (en) | 1995-10-05 | 1999-12-14 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US5830905A (en) | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US6127384A (en) | 1996-03-29 | 2000-10-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5877187A (en) | 1996-06-04 | 1999-03-02 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. (Faes) | Benzimidazole derivatives with antihistaminic activity |
WO1998033802A1 (en) | 1997-02-01 | 1998-08-06 | Newcastle University Ventures Limited | Quinazolinone compounds |
US6303627B1 (en) | 1998-06-19 | 2001-10-16 | Eli Lilly And Company | Inhibitors of serotonin reuptake |
Non-Patent Citations (6)
Title |
---|
Denny, William A., Newcastle, Gordon W. and Baguley, Bruce C., Potential Antitumor Agents. 59. Structure-Activity Relationships for 2-Phenylbenzimidazole-4-carboxamides, a New Class of "Minimal" DNA-Intercalating Agents Which May Not Act via Topoisomerase II, J. Med. Chem., 1990, vol. 33. No. 2, 815-819, University of Auckland School of Medicine, Auckland, New Zealand. |
Iemura, R., Kawashima, T., Fukuda, T., ITO, K. and Tsukamoto, T., Synthesis of Zensimidazole Derivatives as Potential H<SUB>1</SUB>-Antihistaminic Agents, J. Heterocyclic Chem. 24, 31 (1987), Jan.-Feb. 1987, Pharmaceuticals Reserach Center, Kanebo Ltd., 5-90, Tomobuchi-cho 1-Chome, Miyakojima-ku, Osaka, 534, Japan. |
Orjales, Aurelio, Bordell, Maravillas and Rubio, Victor, Synthesis and Structure Activity Relationship of New Piperidinyl and Piperazinyl Derivatives as Antiallergics, J. Heterocylic Chem. 32, 707 (1995), Research Dept., FAES S.A. Bilboa, Spain. |
Wahlgren, Curtis G. and Addison, Anthony W., Synthesis of Some Benzimidazole-, Ryridine- and Imidazole-Derived Chelating Agents, J. Heterocylic Chem., 26, 541 (1989), May-Jun. 1989, Chemistry Dept., Drezel University, Philadelia, PA. |
Zarin, P.P., Lavrinovich, E.S. and Aren, A.K., Pyridinium Salts I. Reduction of 4-(Benzazol-2-yl) Pyridinium Salts in a Neutral Medium, UDC 547.821.3:547-822.1, Institute of Organic Synthesis, Academny of Sciences of the Latvian SSH, Riga. Jan., 1974. |
Zarins, P., Lavinovich, E.S.; Arens, A and Germane, S., Abstract Substituted Piperidines were prepared by condensing piperidinecarboxylic acid with the corresponding o-HZC6H4NH2 at 220-50. degree. in polyphosphoric acid. Institute of Organic Synthesis, Academy of Sciences, Latvia S.S.R. U.S.S.R; CA 80: 146143, 1974. |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7550603B2 (en) | 2005-04-11 | 2009-06-23 | Abbott Laboratories Inc. | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors |
US20060229289A1 (en) * | 2005-04-11 | 2006-10-12 | Gui-Dong Zhu | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors |
US8217070B2 (en) | 2005-04-11 | 2012-07-10 | Abbott Laboratories | 2-substituted-1H-benzimidazole-4-carboxamides are PARP inhibitors |
US20100234425A1 (en) * | 2005-04-11 | 2010-09-16 | Abbott Laboratories | 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors |
US7728026B2 (en) | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
US20060229351A1 (en) * | 2005-04-11 | 2006-10-12 | Gui-Dong Zhu | 2-Substituted-1 H-benzimidazile-4-carboxamides are PARP inhibitors |
US20090076122A1 (en) * | 2005-06-10 | 2009-03-19 | Bipar Sciences, Inc. | PARP Modulators and Treatment of Cancer |
US8377985B2 (en) | 2005-07-18 | 2013-02-19 | Bipar Sciences, Inc. | Treatment of cancer |
US20080319054A1 (en) * | 2005-07-18 | 2008-12-25 | Bipar Sciences, Inc. | Treatment of Cancer |
US20070179136A1 (en) * | 2005-09-29 | 2007-08-02 | Penning Thomas D | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
US20070270476A1 (en) * | 2005-11-15 | 2007-11-22 | Penning Thomas D | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
US7595406B2 (en) | 2005-11-15 | 2009-09-29 | Abbott Laboratories Inc. | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors |
US20090186877A1 (en) * | 2006-05-02 | 2009-07-23 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
US20070259937A1 (en) * | 2006-05-02 | 2007-11-08 | Giranda Vincent L | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
US7999117B2 (en) | 2006-05-02 | 2011-08-16 | Abbott Lab | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors |
US20070292883A1 (en) * | 2006-06-12 | 2007-12-20 | Ossovskaya Valeria S | Method of treating diseases with PARP inhibitors |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
US20080103208A1 (en) * | 2006-09-05 | 2008-05-01 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
US8143447B2 (en) | 2006-09-05 | 2012-03-27 | Bipar Sciences, Inc. | Treatment of cancer |
US20080103104A1 (en) * | 2006-09-05 | 2008-05-01 | Bipar Sciences, Inc. | Treatment of cancer |
US7994222B2 (en) | 2006-09-05 | 2011-08-09 | Bipar Sciences, Inc. | Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds |
US8067613B2 (en) | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
US20090030016A1 (en) * | 2007-07-16 | 2009-01-29 | Abbott Laboratories | Benzimidazole poly(adp ribose)polymerase inhibitors |
US7732491B2 (en) | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
US20100009930A1 (en) * | 2007-11-12 | 2010-01-14 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in conbination with anti-tumor agents |
US20090131529A1 (en) * | 2007-11-12 | 2009-05-21 | Bipar Sciences | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
US20100003192A1 (en) * | 2007-11-12 | 2010-01-07 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
US20090123419A1 (en) * | 2007-11-12 | 2009-05-14 | Bipar Sciences | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
US20100183743A1 (en) * | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
US8093396B2 (en) | 2009-01-19 | 2012-01-10 | Abbott Laboratories | Benzthiazole inhibitors of poly(ADP-ribose)polymerase |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE39608E1 (en) | Substituted benzimidazoles and their use as PARP inhibitors | |
US6737421B1 (en) | Cyclo-alkyl substituted benzimidazoles and their use as PARP inhibitors | |
US6696437B1 (en) | Heterocyclically substituted benzimidazoles, the production and application thereof | |
US7041675B2 (en) | Heterocyclic compounds and their use as PARP inhibitors | |
US6509365B1 (en) | 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof | |
ES2251405T3 (es) | Derivados de benzodiazepina, su obtencion y aplicacion. | |
US20040067949A1 (en) | Substituted indoles which are parp inhibitors | |
US7026311B2 (en) | Dibenzodiazepine derivatives, their preparation and use | |
DE19916460B4 (de) | Substituierte Benzimidazole, deren Herstellung und Anwendung | |
MXPA01005197A (en) | Substituted benzimidazoles and their use as parp inhibitors | |
MXPA01010673A (es) | Benzimidazoles ciclo-alquil substituidos y su uso como inhibidores parp | |
MXPA01004869A (en) | 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof | |
MXPA01011333A (en) | Heterocyclically substituted benzimidazoles, the production and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: ABBVIE DEUTSCHLAND GMBH & CO KG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ABBOTT GMBH & CO KG;REEL/FRAME:030711/0477 Effective date: 20121101 |
|
FPAY | Fee payment |
Year of fee payment: 12 |